source
- REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate CancerSagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.onclive · 3mo ago↗ source
- Second Clinical Scenario - Progressive Disease Despite Hematocrit ControlPolycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.onclive · 3mo ago↗ source
- Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and DiscoveryThe State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.